Treatment of severe Mycobacterium avium complex pulmonary disease with a adjunctive amikacin and clofazimine versus standard regimen alone, a retrospective study Source: International Congress 2019 – Tuberculosis and non-TB mycobacterial infection I Year: 2019
The impact of different antibiotic treatment regimens on mortality in Mycobacterium avium complex pulmonary disease: a population-based cohort study Source: Eur Respir J, 56 (3) 1901875; 10.1183/13993003.01875-2019 Year: 2020
Clinical efficacy and safety of fluoroquinolone containing regimens in patients with Mycobacterium avium complex pulmonary disease Source: Eur Respir J, 55 (4) 1901240; 10.1183/13993003.01240-2019 Year: 2020
Failure with acquired resistance of an optimised bedaquiline-based treatment regimen for pulmonary Mycobacterium avium complex disease Source: Eur Respir J, 54 (1) 1900118; 10.1183/13993003.00118-2019 Year: 2019
A randomized, open-label, multicenter study of liposomal amikacin for inhalation in adult patients with nontuberculous mycobacteria (NTM) lung infections caused by mycobacterium avium complex (MAC) Source: International Congress 2015 – Novel strategies for the management of asthma, COPD and airway infections Year: 2015
Paradoxical response during antibiotic treatment in patients with Mycobacterium avium complex lung disease Source: Virtual Congress 2020 – Non-tuberculous mycobacterial infections and bronchiectasis Year: 2020
Long-term observation of pulmonary Mycobacterium avium complex disease treated with chemotherapy following the guidelines for treatment Source: Annual Congress 2009 - Extrapulmonary tuberculosis and non-tuberculous-mycobacteria (NTM) infections Year: 2009
Association between injectable aminoglycoside treatment duration and outcomes in cavitary Mycobacterium avium complex lung disease Source: International Congress 2018 – Challenges in treating tuberculosis and nontuberculous mycobacteria Year: 2018
Comparison of safety and efficacy between clarithromycin- and azithromycin-containing regimens in Mycobacterium avium complex lung disease Source: International Congress 2019 – Complex respiratory infections in clinical practice Year: 2019
The clinical effect of combined therapy according to guidelines on the treatment of pulmonary Mycobacterium avium complex disease - including a long-term follow-up study Source: Eur Respir J 2004; 24: Suppl. 48, 721s Year: 2004
Combined chemotherapy in Mycobacterium avium complex pulmonary disease Source: Eur Respir J 2005; 26: Suppl. 49, 657s Year: 2005
The effect of combined chemotherapy according to the guidelines on the treatment for Mycobacterium avium complex pulmonary disease Source: Eur Respir J 2002; 20: Suppl. 38, 546s Year: 2002
Clinical characteristics and treatment outcomes of patients with macrolide-resistant Mycobacterium avium complex pulmonary disease: a systemic review and meta-analysis Source: International Congress 2019 – Clinical investigations of non-TB mycobacterial infection Year: 2019
A randomized study of bronchoscopic blockade of the affected part of a lung as a part the complex treatment of patients with drug-resistant pulmonary tuberculosis Source: Annual Congress 2012 - Tuberculosis: invasive diagnostic and therapeutic interventions Year: 2012
Sentinel-site surveillance of Mycobacterium avium complex pulmonary disease Source: Eur Respir J 2005; 26: 1092-1096 Year: 2005
Pulmonary disease caused by M. malmoense in HIV negative patients: 5-yr follow-up of patients receiving standardised treatment Source: Eur Respir J 2003; 21: 478-482 Year: 2003
First data about the efficacy of moxifloxacin in the treatment of pulmonary tuberculosis – a prospective, randomised study versus INH Source: Annual Congress 2003 - Management of tuberculosis and tubercular infection - old and new considerations Year: 2003
Development of mycobacterium tuberculosis additional drug resistance during chemotherapy of disseminated pulmonary tuberculosis Source: Eur Respir J 2007; 30: Suppl. 51, 663s Year: 2007
Efficacy and safety of kanamycin addition in patients with drug-refractory mycobacterium avium complex lung disease Source: International Congress 2015 – Bronchiectasis and NTM infections: clinical and functional characterisation Year: 2015
Switch effects from daily to intermittent treatment with a daily regimen dosage for Mycobacterium avium complex pulmonary disease Source: International Congress 2019 – Clinical and translational studies of bronchiectasis and non-TB mycobacterial infection Year: 2019